Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599812 | 1.00 | ALOX5 (0.45) | ALOX5TRPV1LMNAPTGESKMT2A | |
| SCHEMBL3595116 | 0.99 | TRPV1 (0.46) | ALOX5TRPV1PTGES | |
| SCHEMBL3595119 | 0.99 | TRPV1 (0.46) | ALOX5TRPV1PTGES | |
| SCHEMBL17019976 | 0.82 | TRPV1 (0.48) | TRPV1KMT2A | |
| SCHEMBL3607179 | 0.82 | PPARG (0.46) | TRPV1PTGESKMT2A | |
| SCHEMBL3607181 | 0.82 | PPARG (0.46) | TRPV1PTGESKMT2A | |
| SCHEMBL15702136 | 0.81 | GGPS1 (0.51) | ALOX5TRPV1LMNAKMT2A | |
| SCHEMBL3590181 | 0.79 | PTGES (0.47) | ALOX5TRPV1PTGES | |
| SCHEMBL3609256 | 0.79 | PTGES (0.47) | ALOX5TRPV1PTGES | |
| SCHEMBL8223345 | 0.79 | PTGES (0.47) | ALOX5TRPV1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| EP-2057114-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008015240-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PNMT, PSEN1, SNCA | ALOX5 703/4885TRPV1 1245/4885LMNA 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.